Release Date: 29-Aug-2023
The US FDA approved Epkinly in May 2023, making it the first bispecific antibody to be approved in 2023. Epkinly was co-developed by AbbVie and Genmab, and is indicated for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The active ingredient in the medicine is Epcoritamab, an IgG1-bispecific antibody that binds to CD3 on T cells and CD20 on B cells at the same time, thereby bridging the gap between T cells and lymphoma cells, and speeding the process of cancer cell elimination. Epkinly is undergoing multiple clinical trials in different lymphoma indications, both as monotherapy and in combination with chemotherapies and immunotherapies. Therefore, further FDA approvals for Epkinly seem feasible in the coming years.
DOWNLOAD US Bispecific Antibodies Market and Clinical Pipeline Insight 2028 Report
https://www.kuickresearch.com/report-us-bispecific-antibodies-market